Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Other 1Classical hematology 1

Conditions

Pain, Intractable 1Neoplasms 1Mucositis 1Leukemia 1Bone Marrow Failure Disorders 1Anemia, Aplastic 1

Interventions

pembrolizumab 589Cyclophosphamide 539Magnetic Resonance Spectroscopy 523Radiotherapy 506Specimen Handling 503Nivolumab 407Cisplatin 370Carboplatin 358Biopsy 304Blood Specimen Collection 295Radiosurgery 283Paclitaxel 274Surveys and Questionnaires 268Standard of Care 266Gemcitabine 265fludarabine 261Dexamethasone 258Drug Therapy 256venetoclax 246Bevacizumab 246Oxaliplatin 206Rituximab 195Capecitabine 194Radiation 189Fluorouracil 186Ipilimumab 184durvalumab 180Doxorubicin 175atezolizumab 172Etoposide 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Passive Cutaneous Anaphylaxis × 1 year × Clear all
NCT06940570 2025-10-23

MATCH

University of Texas Southwestern Medical Center

Phase 3 Suspended
60 enrolled
Classical hematologyOtherOther hematologic neoplasm

Bone Marrow Failure Disorders, Anemia, Aplastic, Leukemia, Neoplasms, Pain, Intractable, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡